Disappearance of a GH secreting macroadenoma, during long-term somatostatin analogue administration

Experimental and Clinical Endocrinology and Diabetes

Volumn 117, Issue 7, 2009, Pages 309-311

  Ozbek M ^a   Erdogan, M ^b   Akbal, E ^a   Gonulalan G ^a  

^a Diskapi Education and Research Hospital   (Turkey)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Acromegaly; Adenoma; Disappearance; Pituitary; Somatostatin analogue

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; DRUG DERIVATIVE; SOMATOSTATIN;

ACROMEGALY; ADULT; ARTICLE; CASE REPORT; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; ADENOMA; DELAYED RELEASE FORMULATION; MIDDLE AGED; RADIOGRAPHY; REMISSION; TIME;

ADENOMA; DELAYED-ACTION PREPARATIONS; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; MIDDLE AGED; OCTREOTIDE; REMISSION INDUCTION; SOMATOSTATIN; TIME FACTORS;

EID: 70349567356     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0028-1086000     Document Type: Article

References (31)

1. Swearingen B, Barker FG 2nd, Katznelson L et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83 (10): 3419-3426
2. Bates AS, Van't Hoff W, Jones JM et al. An audit of outcome of treatment in acromegaly. Q J Med 1993; 86 (5): 293-299
3. Biermasz NR, Dulken H van, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000 ; 85 (12) : 4596 - 4602
4. Beauregard C, Truong U, Hardy J et al. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003; 58 (1): 86-91
5. Melmed S, Casanueva FF, Cavagnini F et al. For the acromegaly treatment consensus workshop participants guidelines for acromegaly management. J Clin Endocrinol Metab 2002; 87: 4054-4058
6. Newman CB, Melmed S, George A et al. Octreotide as primary treatment for acromegaly. J Clin Endocrinol Metab 1998; 83: 3034-3040
7. Culler MD. Evolving concepts in the quest for advanced therapeutic analogues of somatostatin. Dig Liver Dis 2004; 36: S17-S25
8. Kaltsas GA, Stefanidou Z, Papadogias D et al. Treatment of advanced neuroendocrine tumours with the radiolabelled somatostatin analogue octreotide. Hormones 2002; 1: 149-156
9. Krassas G, Pontikides N, Dumas A et al. The effect of long-term somatostatin analogue treatment on free and total insulin-like growth factor (IGF) -I, -II, and IGF binding protein -1, -2, and -3 serum levels in euthyroid patients with active thyroid eye disease. Hormones 2004 ;3 : 191 - 197
10. Orme SM, Lamb JT, Nelson M et al. Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide. Postgrad Med 1991; J67:466 - 468
11. Williams G, Ball J, Bloom S et al. Improvement in headache associated with prolactinoma during treatment with a somatostatin analogue: an "N of 1" study. N Engl J Med 1986; 315: 1166-1167
12. Pugnale N, Waridel F, Bouzourene H et al. Pharyngeal pituitary non-functioning adenoma with normal intra-sellar gland: massive tumor shrinkage on octreotide therapy. Eur J Endocrinol 2003 ; 148 :357 - 364
13. Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet 1998 ; 352 : 1455 - 1461
14. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998; 89: 353-358
15. Kaltsas GA, Isidori AM, Florakis D et al. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 2001 ; 86 : 1645 - 1652
16. Newman CB, Melmed S, George A et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3034-3040
17. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003; 24: 28-47
18. Park C, Yang I, Woo et al. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: The relationship with endogenous SRIF activity and response to octreotide. Endocr 2004 ; J 51 : 227 - 236
19. Lundin P, Eden Engstrom B, Karlsson FA et al. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. Am J Neuroradiol 1997; 18: 765-772
20. Newman CB, Melmed S, Snyder PJ et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab 1995 ; 80 : 2768 - 2775
21. Colao A, Ferone D, Marzullo P et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001 ; 86 : 2779 - 2786
22. Plockinger U, Reichel M, Fett U et al. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994; 79: 1416-1423
23. Freda PU, Katznelson L, Lely AJ van der et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005 ; 90 : 4465 - 4473
24. Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol 2003; 58: 471-481
25. Bevan JS, Atkin SL, Atkinson AB et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002 ; 87 : 4554 - 4563
26. Resmini E, Murialdo G, Giusti M et al. Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR. J Endocrinol Invest 2005; 28 (2): 166-169
27. Livadas S, Hadjidakis DJ, Argyropoulou MI et al. Disappearance of a growth hormone secreting macro adenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal . Hormones (Athens) 2006 ; 5 (1) : 57 - 63
28. Harinarayan CV. Primary octreotide LAR therapy in GH-secreting pituitary adenoma. J Indian Med Assoc (abstract) 2004; 102 (5):258 - 260-1
29. Barkan AL, Lloyd RV, Chandler WF et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988; 67: 1040-1048
30. Ezzat S, Kontogeorgos G, Redelmeier DA et al. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 1995 ; 133 : 686 - 690
31. Thapar K, Kovacs KT, Stefaneanu L et al. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clin Proc 1997 ; 72 : 893 - 900